本發明係關於一種複室容器。The present invention relates to a multi-chamber container.
自先前以來，業已知悉為了將藉由靜脈注射對患者投與之二種以上之藥液於無菌狀態下混合使用，而具有複數個室的複室容器。此複室容器於由能夠剝離之分隔壁區劃出之複數個室內將各藥液等分類收容。因而，於即將使用複室容器之前，使分隔壁剝離。藉此，將各室內連通而將藥液混合。In the past, a multi-chamber container having a plurality of chambers has been known in the industry for mixing two or more drug solutions administered to a patient by intravenous injection under a sterile state. The multi-chamber container contains each drug solution separately in a plurality of chambers divided by a partition wall that can be peeled off. Therefore, the partition wall is peeled off just before the multi-chamber container is used. In this way, the chambers are connected to mix the drug solutions.
因複室容器之利用者忘記使藥液混合、或確信已混合，而可能產生對患者投與未混合之藥液之問題。為了防止發生產生此問題，曾作各種適當配置。例如，於日本特開2007-244660號公報中，曾記載在藥劑室之表面設置促使用於藥液混合之壓迫操作之標識。Because the user of the multi-chamber container forgets to mix the drug solution, or believes that it has been mixed, the problem of administering unmixed drug solution to the patient may occur. In order to prevent this problem from occurring, various appropriate configurations have been made. For example, in Japanese Patent Publication No. 2007-244660, it was recorded that a mark for promoting the pressure operation for mixing the drug solution was set on the surface of the drug chamber.
於使用如日本特開2007-244660號公報所揭示之複室容器之情形下，可謂針對促使該複室容器之使用者引起藥液混合之注意，具有效果。然而，為了更確實地防止上述之問題之產生，而有用於更充分進行引起注意之改善餘地。When using a multi-chamber container as disclosed in Japanese Patent Publication No. 2007-244660, it is effective in causing the user of the multi-chamber container to pay attention to the mixing of the drug solutions. However, in order to more reliably prevent the above-mentioned problem from occurring, there is room for improvement in more fully drawing attention.
本發明之一態樣之目的在於提供一種能夠在藥液之投與前防止使用者忘記藥液混合作業之複室容器。解決問題之技術手段One aspect of the present invention is to provide a multi-chamber container that can prevent the user from forgetting to mix the drug solution before administeringthe drug solution .
本發明之一態樣之複室容器係設有吊孔者，且包含：容器本體，其具有收納第1藥劑之第1收納部、收納第2藥劑之第2收納部、及將第1收納部與第2收納部分隔之能夠剝離之分隔部；及密封件，其覆蓋吊孔；且於容器本體與密封件各者顯示用於將第1藥劑與第2藥劑混合之方案。One aspect of the present invention is a multi-chamber container with a hanging hole, and includes: a container body, which has a first storage part for storing a first drug, a second storage part for storing a second drug, and a removable partition part for separating the first storage part from the second storage part; and a seal covering the hanging hole; and a scheme for mixing the first drug and the second drug is displayed on each of the container body and the seal.
於該複室容器中，在容器本體顯示用於將第1藥劑與第2藥劑混合之方案。藉此，於開始使用複室容器時等，使用者可容易地確認用於將第1藥劑與第2藥劑混合之方案。此外，設置於複室容器之吊孔由密封件覆蓋。因而，使用者於使用吊孔懸吊複室容器時，自容器本體去除密封件之至少一部分(例如剝離、或切取等)。此處，於密封件亦顯示上述方案。因此，於在密封件之去除作業時使用者視認密封件時，亦可容易地確認上述方案。如此，於使用複室容器時，使用者因可在複數個時序時確認上述方案，而於藥液之投與前，第1藥劑與第2藥劑之混合作業不易被有意忽略。因此，藉由利用上述複室容器，能夠於藥液之投與前良好地防止使用者忘記藥液混合作業。In the multi-chamber container, a method for mixing the first agent and the second agent is displayed on the container body. Thereby, when starting to use the multi-chamber container, etc., the user can easily confirm the method for mixing the first agent and the second agent. In addition, the hanging hole provided in the multi-chamber container is covered by a seal. Therefore, when the user uses the hanging hole to hang the multi-chamber container, the user removes at least a portion of the seal from the container body (for example, peels off or cuts it off). Here, the above-mentioned method is also displayed on the seal. Therefore, when the user sees the seal during the removal operation of the seal, the above-mentioned method can also be easily confirmed. In this way, when using the multi-chamber container, the user can confirm the above-mentioned method at multiple time sequences, and before the administration of the drug solution, the mixing operation of the first agent and the second agent is not easily intentionally ignored. Therefore, by using the above-mentioned multi-chamber container, it is possible to effectively prevent the user from forgetting the mixing operation of the drug solution before administration of the drug solution.
方案可包含用於將第1藥劑與第2藥劑混合之複數個步序。該情形下，使用者即便為複雜之混合作業，亦可適切地實施藥液混合作業。The protocol may include a plurality of steps for mixing the first agent with the second agent. In this case, the user can appropriately perform the drug solution mixing operation even if the mixing operation is complex.
可行的是，密封件具有覆蓋吊孔之被覆部，顯示於密封件之方案進一步包含用於將吊孔露出之步序。該情形下，當為了利用吊孔而使用者去除密封件時，使用者視認記載於密封件之方案之可能性進一步變高。於藥液之投與前，第1藥劑與第2藥劑之混合作業更不易被有意忽略。此外，使用者藉由確認上述步序，可適切地實施吊孔之露出工序。It is feasible that the seal has a covering portion covering the hanging hole, and the scheme displayed on the seal further includes a step for exposing the hanging hole. In this case, when the user removes the seal to use the hanging hole, the possibility of the user visually recognizing the scheme recorded on the seal becomes higher. Before the administration of the drug solution, the mixing operation of the first drug and the second drug is less likely to be intentionally overlooked. In addition, by confirming the above-mentioned steps, the user can appropriately implement the process of exposing the hanging hole.
可行的是，上述複室容器進一步包含摺翼部，該摺翼供設置吊孔且自容器本體之上緣延伸，密封件將摺翼部固定於容器本體上。此外，可行的是，摺翼部之寬度較容器本體之寬度小，密封件覆蓋摺翼部。該情形下，可將摺翼部確實地固定於容器本體上。It is feasible that the above-mentioned multi-chamber container further comprises a flap portion, the flap portion is provided with a hanging hole and extends from the upper edge of the container body, and the sealing member fixes the flap portion to the container body. In addition, it is feasible that the width of the flap portion is smaller than the width of the container body, and the sealing member covers the flap portion. In this case, the flap portion can be securely fixed to the container body.
可行的是，於密封件設置促使第1藥劑與第2藥劑之混合之第1混合促進標識，於在摺翼部中貼附密封件之面的相背側之背面設置促使第1藥劑與第2藥劑之混合之第2混合促進標識。該情形下，於使用複室容器時，使用者自複室容器之正側及背側之任一側均可確認混合促進標識。於藥液之投與前，第1藥劑與第2藥劑之混合作業更不易被有意忽略。It is feasible to provide a first mixing promotion mark for promoting mixing of the first and second drugs on the sealing member, and to provide a second mixing promotion mark for promoting mixing of the first and second drugs on the back side opposite to the side to which the sealing member is attached in the flap portion. In this case, when using the multi-chamber container, the user can confirm the mixing promotion mark from either the front side or the back side of the multi-chamber container. Before the administration of the drug solution, the mixing operation of the first and second drugs is less likely to be intentionally overlooked.
在前視下，密封件之大小為容器本體之大小之5%以上且30%以下，於密封件，除方案外，亦設置促使第1藥劑與第2藥劑之混合之混合促進標識，於密封件中，方案中所含之文字之尺寸、與混合促進標識中所含之文字之尺寸各者基於視認性之觀點可為7 pt以上，亦可為72 pt以下。該情形下，於密封件，用於將第1藥劑與第2藥劑混合之方案中所含之文字、與混合促進標識中所含之文字兩者對使用者而言能夠容易地視認。因而，於藥液之投與前，第1藥劑與第2藥劑之混合作業更不易被有意忽略。此外，密封件之大小為能夠記載所有上述文字。In front view, the size of the seal is not less than 5% and not more than 30% of the size of the container body. In addition to the scheme, the seal is also provided with a mixing promotion mark that promotes the mixing of the first drug and the second drug. In the seal, the size of the text contained in the scheme and the size of the text contained in the mixing promotion mark can each be not less than 7 pt and can also be not more than 72 pt based on the viewpoint of visibility. In this case, in the seal, the text contained in the scheme for mixing the first drug and the second drug and the text contained in the mixing promotion mark can both be easily recognized by the user. Therefore, before the administration of the drug solution, the mixing operation of the first drug and the second drug is less likely to be intentionally overlooked. In addition, the size of the seal is capable of recording all of the above-mentioned texts.
於容器本體之表面顯示方案，在密封件將摺翼部固定於容器本體上時，顯示於容器本體之方案中所含之文字之方向、與顯示於密封件之方案中所含之文字之方向可於上下方向上互為相同。該情形下，複室容器之使用者自容器本體之正側、背側之任一側均可視認上述方案。The scheme is displayed on the surface of the container body. When the sealing member fixes the flap portion to the container body, the direction of the text contained in the scheme displayed on the container body and the direction of the text contained in the scheme displayed on the sealing member can be the same in the vertical direction. In this case, the user of the multi-chamber container can recognize the above scheme from either the front side or the back side of the container body.
可行的是，於將容器本體沿著分隔部摺疊時，能夠視認顯示於容器本體之方案與顯示於密封件之方案各者。該情形下，即便於將複室容器摺疊之情形下，使用者亦可容易地視認上述方案兩者。It is feasible that when the container body is folded along the partition, the scheme displayed on the container body and the scheme displayed on the seal can be visually recognized. In this case, even when the multi-chamber container is folded, the user can easily visually recognize both of the above schemes.
可行的是，於容器本體中，在重疊於第1收納部之第1部分顯示方案之一部分，在重疊於第2收納部之第2部分顯示方案之另一部分，分隔部藉由第1部分或第2部分經壓迫而剝離。該情形下，即便於在使用者之壓迫作業中無法視認第1部分或第2部分之情形下，使用者亦可視認上述方案之至少一部分。發明之效果It is feasible that in the container body, in one part of the first display scheme overlapping the first storage portion, and in another part of the second display scheme overlapping the second storage portion, the partition is peeled off by the first part or the second part under pressure. In this case, even if the user cannot see the first part or the second part during the pressing operation, the user can still see at least a part of the above scheme.Effect of the invention
根據本發明之態樣，可提供一種能夠在藥液之投與前防止使用者忘記藥液混合作業之複室容器。According to the aspect of the present invention, a multi-chamber container can be provided which can prevent the user from forgetting the mixing operation of the drug solution before administration of the drug solution.
以下，參照附圖，針對本發明之一態樣之較佳之實施形態詳細說明。此外，於以下之說明中，對同一要素或具有同一功能之要素使用同一符號，且省略重複之說明。In the following, with reference to the attached drawings, a preferred embodiment of one aspect of the present invention is described in detail. In addition, in the following description, the same symbol is used for the same element or the element with the same function, and repeated description is omitted.
圖1係實施形態之複室容器之前視圖。圖2係實施形態之複室容器之後視圖。圖3係即將使用之前之複室容器之前視圖。於圖1及圖2中顯示使用前之複室容器，於圖3中顯示即將使用之前之複室容器。圖1～圖3所示之複室容器1例如係獨立地收容輸液用之複數種藥液各者之容器。複室容器1具有：容器本體2、自容器本體2之一端2a延伸之摺翼部3、設置於摺翼部3之吊孔4、覆蓋吊孔4之密封件5、連接於容器本體2之內部之端口6、及封蓋端口6之前端6a之密封件7。以下，將圖1～圖3所示之方向X設為複室容器1之上下方向，將方向Y設為複室容器1之寬度方向。又，將與方向X、Y兩者正交之方向設為複室容器1之厚度方向。因而，容器本體2之一端2a相當於容器本體2之上緣。FIG. 1 is a front view of a multi-chamber container of an embodiment. FIG. 2 is a rear view of a multi-chamber container of an embodiment. FIG. 3 is a front view of a multi-chamber container immediately before use. FIG. 1 and FIG. 2 show the multi-chamber container before use, and FIG. 3 shows the multi-chamber container immediately before use. The multi-chamber container 1 shown in FIG. 1 to FIG. 3 is, for example, a container for independently accommodating each of a plurality of kinds of drug solutions for infusion. The multi-chamber container 1 has: a container body 2, a folding wing portion 3 extending from one end 2a of the container body 2, a hanging hole 4 provided in the folding wing portion 3, a sealing member 5 covering the hanging hole 4, a port 6 connected to the interior of the container body 2, and a sealing member 7 covering the front end 6a of the port 6. Hereinafter, the direction X shown in FIG. 1 to FIG. 3 is set as the up-down direction of the multi-chamber container 1, and the direction Y is set as the width direction of the multi-chamber container 1. Furthermore, a direction perpendicular to both directions X and Y is defined as a thickness direction of the multi-chamber container 1. Therefore, one end 2a of the container body 2 corresponds to an upper edge of the container body 2.
容器本體2係示出可撓曲性之袋狀之成形構件。容器本體2之形狀無特別限定，例如為大致長方形狀。容器本體2例如藉由將示出可撓曲性之2張膜熱接著而成形。該膜為透明且示出可撓曲性之塑膠膜，可具有單層構造，亦可具有積層構造。於膜具有積層構造之情形下，該膜例如包含聚乙烯膜即外層、多環烯烴膜即中間層、及聚乙烯與聚丙烯之混合膜即內層。沿著方向X之容器本體2之尺寸為例如15 cm以上且30 cm以下，沿著方向Y之容器本體2之尺寸為例如15 cm以上且25 cm以下。因而，前視之容器本體2之面積為例如225 cm2以上且750 cm2以下。基於各藥劑之收容量之觀點，上述面積為例如400 cm2以上。此外，本說明書之「透明」意指可見光之透過率為規定之比例以上(例如55%以上)。換言之，本說明書之「透明」為亦包含半透明之概念。又，膜之至少一部分可被著色。The container body 2 is a bag-shaped forming member showing flexibility. The shape of the container body 2 is not particularly limited, and is, for example, roughly rectangular. The container body 2 is formed, for example, by thermally bonding two films showing flexibility. The film is a transparent plastic film showing flexibility, and may have a single-layer structure or a laminated structure. In the case where the film has a laminated structure, the film includes, for example, a polyethylene film as an outer layer, a polycyclic olefin film as an intermediate layer, and a mixed film of polyethylene and polypropylene as an inner layer. The size of the container body 2 along the direction X is, for example, greater than 15 cm and less than 30 cm, and the size of the container body 2 along the direction Y is, for example, greater than 15 cm and less than 25 cm. Therefore, the area of the container body 2 viewed from the front is, for example, greater than 225cm2 and less than 750cm2 . Based on the viewpoint of the volume of each drug, the above area is, for example, 400cm2 or more. In addition, "transparent" in this specification means that the transmittance of visible light is above a specified ratio (for example, above 55%). In other words, "transparent" in this specification is a concept that also includes translucency. In addition, at least a portion of the film can be colored.
容器本體2具有：第1收納部21、第2收納部22、及將第1收納部21與第2收納部22分隔之能夠剝離之分隔部23。第1收納部21為收納第1藥劑之部分，由容器本體2之外緣2b與分隔部23區劃成。第1收納部21位於較分隔部23靠下側，且與端口6連通。第2收納部22為收納與第1藥劑不同之第2藥劑之部分，由容器本體2之外緣2b與分隔部23區劃成。第2收納部22位於較分隔部23靠上側。藉由將第1藥劑與第2藥劑相互獨立地收容於容器本體2，可將若混合並長期存放則穩定性低之第1藥劑與第2藥劑以不混合之狀態存放。因而，可抑制第1藥劑與第2藥劑之劣化。The container body 2 has a first storage portion 21, a second storage portion 22, and a detachable partition 23 that separates the first storage portion 21 from the second storage portion 22. The first storage portion 21 is a portion for storing a first drug, and is defined by the outer edge 2b of the container body 2 and the partition 23. The first storage portion 21 is located below the partition 23 and is connected to the port 6. The second storage portion 22 is a portion for storing a second drug different from the first drug, and is defined by the outer edge 2b of the container body 2 and the partition 23. The second storage portion 22 is located above the partition 23. By storing the first drug and the second drug independently in the container body 2, the first drug and the second drug, which would have low stability if mixed and stored for a long time, can be stored in an unmixed state. Therefore, the degradation of the first drug and the second drug can be suppressed.
第1藥劑與第2藥劑各者為液體、固體(亦包含粉末、凝膠等)、或氣體之內容物。於本實施形態中，第1藥劑與第2藥劑各者為透明，但不限定於此，可為半透明，亦可為不透明。第1藥劑與第2藥劑各者可為無色，亦可被著色。基於分隔部23之易剝離容易性之觀點，較佳為第1藥劑與第2藥劑之至少一者為藥液。於本實施形態中，第1藥劑與第2藥劑各者一般而言為作為輸液而使用者(例如靜脈投與用營養輸液)。於第1藥劑與第2藥劑各者為靜脈投與用營養輸液之情形下，例如，第1藥劑為糖液，第2藥劑為胺基酸液。此外，作為靜脈投與用營養輸液，可為中心靜脈投與用營養輸液、末梢靜脈投與用營養輸液等之輸液。糖液中所含之糖可為例如還原糖，亦可為葡萄糖。於糖液中，除糖以外，亦可含有電解質、pH調整劑、維他命B1、B2、B6、B12等水溶性維他命。於糖液中，可與表面活性劑一同含有維他命A、D、E等脂溶性維他命。糖液之組成、pH等可根據患者之病情等而適當變更。胺基酸液中所含之胺基酸可為胺基酸本身，亦可為N-乙醯衍生物等之胺基酸之衍生物。於胺基酸液中，除胺基酸以外，亦可含有電解質、pH調整劑、維他命C等水溶性維他命。胺基酸液之組成、pH等可根據患者之病情等而適當變更。或，第1藥劑與第2藥劑可為灌流液，亦可為透析液，還可為保存液。The first drug and the second drug are each a liquid, a solid (including powders, gels, etc.), or a gas. In the present embodiment, the first drug and the second drug are each transparent, but are not limited thereto, and may be translucent or opaque. The first drug and the second drug may be colorless or colored. From the perspective of easy peeling of the partition 23, it is preferred that at least one of the first drug and the second drug is a liquid medicine. In the present embodiment, the first drug and the second drug are each generally used as an infusion (e.g., a nutrient infusion for intravenous administration). In the case where the first agent and the second agent are each an intravenous nutrient infusion, for example, the first agent is a sugar solution and the second agent is an amino acid solution. In addition, as the intravenous nutrient infusion, it can be an infusion of a central intravenous nutrient infusion, a peripheral intravenous nutrient infusion, etc. The sugar contained in the sugar solution can be, for example, a reducing sugar or glucose. In addition to sugar, the sugar solution can also contain electrolytes, pH adjusters, and water-soluble vitamins such as vitamin B1, B2, B6, and B12. The sugar solution can contain fat-soluble vitamins such as vitamins A, D, and E together with a surfactant. The composition and pH of the sugar solution can be appropriately changed according to the patient's condition, etc. The amino acid contained in the amino acid solution may be the amino acid itself or a derivative of the amino acid such as an N-acetyl derivative. In addition to the amino acid, the amino acid solution may also contain electrolytes, pH adjusters, water-soluble vitamins such as vitamin C. The composition and pH of the amino acid solution may be appropriately changed according to the patient's condition. Alternatively, the first agent and the second agent may be a perfusion fluid, a dialysate, or a storage fluid.
分隔部23係藉由對容器本體2施加壓力(例如，使用者對第1收納部21或第2收納部22之沿著厚度方向之按壓力)而能夠剝離之弱密封件部。藉由剝離分隔部23，而第1收納部21與第2收納部22相互連通，第1藥劑與第2藥劑混合。分隔部23沿著方向Y延伸，將第1收納部21與第2收納部22分隔。分隔部23具有方向Y之中央部23a、及於方向Y上夾著中央部23a之一對側部23b、23b。於方向X上，中央部23a之寬度較各側部23b之寬度小。此外。各側部23b之寬度之至少一部分越靠近中央部23a，越窄。藉此，於將上述壓力施加於容器本體2時，第1藥劑或第2藥劑容易集中於中央部23a，容易剝離中央部23a。The partition 23 is a weak seal portion that can be peeled off by applying pressure to the container body 2 (for example, a user applies pressure along the thickness direction to the first storage portion 21 or the second storage portion 22). By peeling off the partition 23, the first storage portion 21 and the second storage portion 22 are connected to each other, and the first drug and the second drug are mixed. The partition 23 extends along the direction Y to separate the first storage portion 21 and the second storage portion 22. The partition 23 has a central portion 23a in the direction Y, and a pair of side portions 23b, 23b sandwiching the central portion 23a in the direction Y. In the direction X, the width of the central portion 23a is smaller than the width of each side portion 23b. In addition. At least a portion of the width of each side portion 23b is narrower as it approaches the central portion 23a. Thus, when the pressure is applied to the container body 2, the first drug or the second drug is easily concentrated in the central portion 23a and easily peeled off the central portion 23a.
如圖1所示，於容器本體2之表面顯示用於將第1藥劑與第2藥劑混合之方案100。方案100係包含文字、色、記號及圖之至少一者之標識，例如印刷於容器本體2之表面。文字為日語、英語、簡體字、繁體字、數字等。於本實施形態中，在方案100中，在紅色之背景顯示白色空心之文字、記號及圖之至少一者。顯示於容器本體2之方案100中所含之文字之方向在前視下正立。方案100包含用於將第1藥劑與第2藥劑混合之複數個步序。於本實施形態中，方案100包含第1步序101、第2步序102、及第3步序103。於在厚度方向上重疊於第1收納部21之容器本體2之第1部分2c、與在厚度方向上重疊於分隔部23之容器本體2之中央部分2f，顯示第1步序101(方案100之一部分)。於在厚度方向上重疊於第2收納部22之容器本體2之第2部分2d及第3部分2e，分別顯示第2步序102(方案100之另一部分)及第3步序103(方案100之又一部分)。此外，於圖2中省略方案100。又，可於容器本體2之表面，設置與方案100不同之標識(例如，示出商品名之標識、示出內容物之容量之標識等)。As shown in FIG. 1 , a scheme 100 for mixing the first drug with the second drug is displayed on the surface of the container body 2. The scheme 100 is a label including at least one of text, color, mark and figure, for example, printed on the surface of the container body 2. The text is Japanese, English, simplified Chinese, traditional Chinese, numbers, etc. In this embodiment, in the scheme 100, at least one of white hollow text, mark and figure is displayed on a red background. The direction of the text contained in the scheme 100 displayed on the container body 2 is upright in front view. The scheme 100 includes a plurality of steps for mixing the first drug with the second drug. In this embodiment, the scheme 100 includes a first step 101, a second step 102, and a third step 103. The first step 101 (a part of the solution 100) is shown on the first part 2c of the container body 2 overlapping the first storage part 21 in the thickness direction, and the central part 2f of the container body 2 overlapping the partition part 23 in the thickness direction. The second step 102 (another part of the solution 100) and the third step 103 (another part of the solution 100) are shown on the second part 2d and the third part 2e of the container body 2 overlapping the second storage part 22 in the thickness direction, respectively. In addition, the solution 100 is omitted in FIG. 2. In addition, a label different from the solution 100 (for example, a label showing a product name, a label showing the capacity of the content, etc.) can be set on the surface of the container body 2.
第1步序101與第2步序102及第3步序103各者具體地說明第1藥劑與第2藥劑之混合作業。第1步序101包含：顯示在開始使用複室容器1時壓迫容器本體2之部位之標識101a、顯示在容器本體2之壓迫時傳遞之方向之標識101b、及顯示開通分隔部23之意旨之標識101c。標識101a、101b設置於第1部分2c，標識101c設置於中央部分2f。標識101a重疊於第1收納部21之中央部，但不限於此。例如，於方向X上，標識101a可較第1收納部21之中心更靠近端口6，亦可較第1收納部21之中心更靠近分隔部23。例如，藉由依照標識101a之內容，使用者壓迫第1部分2c，可容易地剝離分隔部23。此時，因使用者將手放於第1部分2c，而標識101a被遮蔽，標識101b之至少一部分、與設置於中央部分2f之標識101c未被遮蔽。基於實施藉由第1部分2c之壓迫實現之分隔部23之剝離、及確認該壓迫時之標識101c之等之觀點，標識101a、101c越遠離，越佳。標識101a、101b、101c各者包含文字及圖之至少一者，但不限於此。第2步序102包含顯示將第1藥劑與第2藥劑混合之意旨之標識。於本實施形態中，第2步序102之標識為與第1步序101之標識101a、101b之關聯性高之內容。因而，第2步序102可位於第2收納部22之第1步序101之附近。例如，顯示在壓迫時傳遞之力之方向之標識101b不僅設置於第1部分2c，亦可設置於第2部分2d。該情形下，第2步序102可與標識101b重疊而顯示。第3步序103包含剝除密封件5中所含之被覆部51(細節於後文敘述)而於吊孔4處露出之意旨之標識。於本實施形態中，第3步序103與第2步序102進行比較，為與第1步序101之關聯性低之內容。因而，第3步序103可較第2步序102相對於第1步序101更遠離。於本實施形態中，第3部分2e較第2部分2d相對於第1部分2c更遠離。基於使用者可於短時間確認各標識之觀點，標識101a、101b、101c、第2步序102、及第3步序103各者中所含之文字數例如為8個文字以下、或6個文字以下。The first step 101, the second step 102, and the third step 103 each specifically describe the mixing operation of the first drug and the second drug. The first step 101 includes: a mark 101a indicating the position of the container body 2 when the multi-chamber container 1 is used, a mark 101b indicating the direction of transmission when the container body 2 is pressed, and a mark 101c indicating the intention of opening the partition 23. The marks 101a and 101b are set on the first part 2c, and the mark 101c is set on the central part 2f. The mark 101a overlaps the central part of the first storage part 21, but is not limited to this. For example, in the direction X, the mark 101a may be closer to the port 6 than the center of the first storage portion 21, or may be closer to the partition 23 than the center of the first storage portion 21. For example, by pressing the first portion 2c according to the content of the mark 101a, the partition 23 can be easily peeled off. At this time, because the user puts his hand on the first portion 2c, the mark 101a is shielded, and at least a part of the mark 101b and the mark 101c set in the central portion 2f are not shielded. Based on the viewpoints of implementing the peeling of the partition 23 achieved by pressing the first portion 2c and confirming the mark 101c when the pressing is performed, the farther the marks 101a and 101c are, the better. Each of the labels 101a, 101b, and 101c includes at least one of text and a picture, but is not limited thereto. The second step 102 includes a label indicating that the first drug and the second drug are mixed. In this embodiment, the label of the second step 102 is a content that is highly related to the labels 101a and 101b of the first step 101. Therefore, the second step 102 can be located near the first step 101 of the second storage portion 22. For example, the label 101b indicating the direction of the force transmitted during compression is not only provided in the first portion 2c, but also in the second portion 2d. In this case, the second step 102 can be displayed overlapping with the label 101b. The third step 103 includes a mark to remove the covering portion 51 (details will be described later) included in the seal 5 and expose it at the hanging hole 4. In this embodiment, the third step 103 is less related to the first step 101 than the second step 102. Therefore, the third step 103 can be farther away from the first step 101 than the second step 102. In this embodiment, the third part 2e is farther away from the first part 2c than the second part 2d. From the viewpoint that the user can recognize each label in a short time, the number of characters contained in each of the labels 101a, 101b, 101c, the second step 102, and the third step 103 is, for example, 8 characters or less, or 6 characters or less.
摺翼部3為與容器本體2之外緣2b同時形成之部分，設置有吊孔4。如圖1及圖2所示，於使用前之複室容器1中，摺翼部3朝向第2收納部22摺疊。另一方面，如圖3所示，於即將使用之前之複室容器1中，摺翼部3以於方向X上自容器本體2之上緣遠離容器本體2之方式延伸。此處，於使用前之複室容器1中，摺翼部3藉由密封件5固定於容器本體2之背面上。換言之，於使用前之複室容器1中，密封件5無破損地貼附於摺翼部3與容器本體2之背面。藉此，即便於將多數個複室容器1裝箱時等，亦可將摺翼部3確實地固定於容器本體2上。此外，由於在密封件5中不易去除封蓋吊孔4之部分，故可防止在分隔部23之開通操作之實施前作業者去除密封件5之上述部分等之對於複室容器1之非意圖之操作。進而，藉由密封件5固定摺翼部3，可抑制由摺翼部3引起之複室容器1之損傷。沿著方向Y之摺翼部3之寬度較容器本體2之寬度小。藉此，於摺疊摺翼部3時等，可良好地抑制由摺翼部3引起之複室容器1之損傷。例如，摺翼部3之寬度為容器本體2之寬度之70%以上且90%以下。The flap portion 3 is a portion formed simultaneously with the outer edge 2b of the container body 2, and is provided with a hanging hole 4. As shown in Figures 1 and 2, in the multi-chamber container 1 before use, the flap portion 3 is folded toward the second storage portion 22. On the other hand, as shown in Figure 3, in the multi-chamber container 1 immediately before use, the flap portion 3 extends in a direction X from the upper edge of the container body 2 away from the container body 2. Here, in the multi-chamber container 1 before use, the flap portion 3 is fixed to the back of the container body 2 by the sealing member 5. In other words, in the multi-chamber container 1 before use, the sealing member 5 is attached to the flap portion 3 and the back of the container body 2 without damage. Thereby, even when a plurality of multi-chamber containers 1 are packed in a box, the flap portion 3 can be securely fixed to the container body 2. In addition, since it is difficult to remove the portion of the sealing member 5 that seals the hanging hole 4, it is possible to prevent the operator from performing unintentional operations on the multi-chamber container 1, such as removing the portion of the sealing member 5 before the opening operation of the partition 23 is performed. Furthermore, by fixing the flap portion 3 with the sealing member 5, damage to the multi-chamber container 1 caused by the flap portion 3 can be suppressed. The width of the flap portion 3 along the direction Y is smaller than the width of the container body 2. Thereby, when the flap portion 3 is folded, etc., damage to the multi-chamber container 1 caused by the flap portion 3 can be well suppressed. For example, the width of the flap portion 3 is not less than 70% and not more than 90% of the width of the container body 2.
吊孔4係為了將複室容器1掛於支架等之掛鉤而設置之部分。吊孔4例如在摺翼部3中設置於方向Y之中央部，在前視下具有圓形狀。The hanging hole 4 is a portion provided for hanging the multi-chamber container 1 on a hook of a stand, etc. The hanging hole 4 is provided, for example, at the center of the flap portion 3 in the direction Y and has a circular shape in front view.
圖4係密封件之放大圖。如圖2及圖4所示，密封件5係於使用前之複室容器1中將摺翼部3固定於容器本體2上且覆蓋吊孔4之構件。密封件5係顯示出可撓曲性且具有帶形狀之密封構件，其貼附於容器本體2之背面及摺翼部3。於將摺翼部3固定於容器本體2上時，密封件5覆蓋摺翼部3。藉此，可防止對複室容器1之非意圖之操作，且可抑制由摺翼部3之角等引起之容器本體2等之損傷。構成密封件5之材料無特別限制，可舉出紙、合成紙、粉紙、布、聚丙烯、聚乙烯等之塑膠膜等。FIG4 is an enlarged view of the seal. As shown in FIG2 and FIG4, the seal 5 is a member that fixes the flap portion 3 to the container body 2 and covers the hanging hole 4 in the multi-chamber container 1 before use. The seal 5 is a sealing member that is flexible and has a band shape, and is attached to the back of the container body 2 and the flap portion 3. When the flap portion 3 is fixed to the container body 2, the seal 5 covers the flap portion 3. Thereby, unintentional operation of the multi-chamber container 1 can be prevented, and damage to the container body 2, etc. caused by the corner of the flap portion 3, etc. can be suppressed. The material constituting the seal 5 is not particularly limited, and paper, synthetic paper, powder paper, cloth, plastic film such as polypropylene and polyethylene, etc. can be cited.
在前視下，密封件5之大小例如為容器本體2之大小之5%以上且30%以下，亦可為10%以上且20%以下。藉由密封件5之大小為容器本體2之大小之5%以上，而充分設置以下詳細敘述之各標識。密封件之大小之下限值例如為容器本體2之大小之8%、10%、或12%。密封件之大小之上限值例如為容器本體2之大小之25%、22%、20%、18%、或16%以下。於方向X上，密封件5之尺寸例如為容器本體2之尺寸之5%以上且20%以下。於方向Y上，密封件5之尺寸例如為容器本體2之尺寸之85%以上且95%以下。前視之密封件5之面積例如為50 cm2以上且100 cm2以下。In front view, the size of the seal 5 is, for example, greater than 5% and less than 30% of the size of the container body 2, or may be greater than 10% and less than 20%. By making the size of the seal 5 greater than 5% of the size of the container body 2, the various markings described in detail below are fully provided. The lower limit of the size of the seal is, for example, 8%, 10%, or 12% of the size of the container body 2. The upper limit of the size of the seal is, for example, 25%, 22%, 20%, 18%, or less than 16% of the size of the container body 2. In direction X, the size of the seal 5 is, for example, greater than 5% and less than 20% of the size of the container body 2. In direction Y, the size of the seal 5 is, for example, greater than 85% and less than 95% of the size of the container body 2. The area of the seal 5 in front view is, for example, greater than 50cm2 andless than 100 cm2.
於密封件5設置：構成為在使用時能夠開通吊孔4之被覆部51、及位於被覆部51之周圍之至少一部分之缺口52(第1易開裂處理部)。於使用前之複室容器1中，被覆部51係覆蓋吊孔4之部分。於被覆部51設置顯示吊孔4之位置之意旨之標識，但不限於此。因存在缺口52，而伴隨著被覆部51之按壓，而容易地開通吊孔4。於開通吊孔4後，被覆部51之一部分可與密封件5相連。該情形下，由於能夠不自密封件5切離被覆部51而實現吊孔4之開通，故垃圾之量減少。The sealing member 5 is provided with: a covering portion 51 which is configured to open the hanging hole 4 when in use, and a notch 52 (a first easily crackable portion) which is located at least in a portion around the covering portion 51. In the multi-chamber container 1 before use, the covering portion 51 is a portion covering the hanging hole 4. A mark indicating the position of the hanging hole 4 is provided on the covering portion 51, but is not limited thereto. Due to the presence of the notch 52, the hanging hole 4 can be easily opened by pressing the covering portion 51. After the hanging hole 4 is opened, a portion of the covering portion 51 can be connected to the sealing member 5. In this case, since the hanging hole 4 can be opened without cutting the covering portion 51 from the sealing member 5, the amount of garbage is reduced.
於密封件5設置穿孔線53(第2易開裂處理部)，該穿孔線在第1收納部21經壓迫時，解除密封件5對摺翼部3之固定。藉此，可與藉由上述壓迫剝離分隔部23同時，解除摺翼部3之固定。因此，可將用於使用複室容器1之步序簡略化。穿孔線53例如沿著摺翼部3之緣之整體設置。該情形下，可容易地解除密封件5對摺翼部3之固定。The seal 5 is provided with a perforated line 53 (second easy-to-break treated portion), which releases the seal 5 from fixing the flap portion 3 when the first storage portion 21 is pressed. Thus, the flap portion 3 can be released from fixing at the same time as the partition portion 23 is peeled off by the above-mentioned pressing. Therefore, the steps for using the multi-chamber container 1 can be simplified. The perforated line 53 is, for example, provided along the entire edge of the flap portion 3. In this case, the seal 5 can be easily released from fixing the flap portion 3.
於密封件5，與容器本體2同樣，顯示用於將第1藥劑與第2藥劑混合之方案200。此外，於密封件5，設置促使第1藥劑與第2藥劑之混合之標識210(混合促進標識)。On the sealing member 5, as on the container body 2, a scheme 200 for mixing the first drug and the second drug is displayed. In addition, on the sealing member 5, a mark 210 (mixing promotion mark) for promoting mixing of the first drug and the second drug is provided.
方案200為包含文字、記號及圖之至少一者之標識，例如印刷於密封件5之表面。於本實施形態中，在方案200中，在紅色之背景顯示白色空心之文字、記號及圖之至少一者。如圖2所示，在解除摺翼部3之固定之前，顯示於密封件5之方案200中所含之文字之方向在前視下正立。因此，於使用前之複室容器1中，顯示於容器本體2之方案100中所含之文字之方向、與顯示於密封件5之方案200中所含之文字之方向各者於方向X上為相同。另一方面，於解除摺翼部3之固定，如圖3所示般複室容器1為即將使用之前時，方案100中所含之文字之方向、與方案200中所含之文字之方向於方向X上互為相反。此處，如上述般，容器本體2、第1藥劑、及第2藥劑各者為透明。因而，如圖5所示，於以密封件5位於內側之方式將容器本體2沿著分隔部23摺疊時，方案100中所含之文字、與方案200中所含之文字兩者在前視下能夠視認。此時，方案100中所含之文字之方向、與方案200中所含之文字之方向於方向X上互為相反。Scheme 200 is a mark including at least one of text, mark and figure, for example, printed on the surface of the seal 5. In this embodiment, in scheme 200, at least one of white hollow text, mark and figure is displayed on a red background. As shown in FIG2, before the fixing of the flap portion 3 is released, the direction of the text contained in scheme 200 displayed on the seal 5 is upright when viewed from the front. Therefore, in the multi-chamber container 1 before use, the direction of the text contained in scheme 100 displayed on the container body 2 and the direction of the text contained in scheme 200 displayed on the seal 5 are the same in direction X. On the other hand, when the fixing of the flap portion 3 is released and the multi-chamber container 1 is about to be used as shown in FIG3, the direction of the text contained in scheme 100 and the direction of the text contained in scheme 200 are opposite to each other in direction X. Here, as described above, the container body 2, the first drug, and the second drug are each transparent. Therefore, as shown in FIG5 , when the container body 2 is folded along the partition 23 with the seal 5 located inside, the text included in the scheme 100 and the text included in the scheme 200 can both be seen from the front. At this time, the direction of the text included in the scheme 100 and the direction of the text included in the scheme 200 are opposite to each other in the direction X.
方案200與方案100同樣包含用於將第1藥劑與第2藥劑混合之複數個步序。藉此，複室容器1之利用者可掌握用於自密封件5與容器本體2兩者將第1藥劑與第2藥劑混合之步序。於本實施形態中，方案200包含：第1步序201，其顯示在開始使用複室容器1時開通分隔部23；第2步序202，其顯示使第1藥劑與第2藥劑混合，及第3步序203，其用於剝除被覆部51而於吊孔4處露出。第1步序201對應於方案100之第1步序101，第2步序202對應於方案100之第2步序102，第3步序203對應於方案100之第3步序103。此外，第1步序201就不具有相當於顯示進行壓迫之部位之標識101a之標識、及相當於顯示在容器本體2之壓迫時傳遞之力之方向之標識101b之標識之點，與第1步序101不同。第1步序201、第2步序202、及第3步序203於方向Y上依序配置，但不限於此。例如，可依序配置第3步序203、第1步序201、及第2步序202。Scheme 200 includes a plurality of steps for mixing the first agent and the second agent, similarly to scheme 100. Thus, the user of the multi-chamber container 1 can grasp the steps for mixing the first agent and the second agent from both the sealing member 5 and the container body 2. In this embodiment, scheme 200 includes: a first step 201, which shows opening the partition 23 when the multi-chamber container 1 is first used; a second step 202, which shows mixing the first agent and the second agent, and a third step 203, which is used to remove the covering portion 51 and expose it at the hanging hole 4. The first step 201 corresponds to the first step 101 of the solution 100, the second step 202 corresponds to the second step 102 of the solution 100, and the third step 203 corresponds to the third step 103 of the solution 100. In addition, the first step 201 does not have a mark corresponding to the mark 101a indicating the location to be pressed and a mark corresponding to the mark 101b indicating the direction of the force transmitted when the container body 2 is pressed, which is different from the first step 101. The first step 201, the second step 202, and the third step 203 are arranged in sequence in the direction Y, but are not limited to this. For example, the third step 203, the first step 201, and the second step 202 can be arranged in sequence.
標識210係誘導使用者實施第1藥劑與第2藥劑之混合(即分隔部23之開通)之標識。標識210中所含之文字之方向在前視下倒立。因而，如圖3所示，於即將使用之前之複室容器1中，標識210之內容在前視下能夠容易地辨識。因此，例如，於經由吊孔4將複室容器1鉤掛於掛鉤等時等，可充分發揮標識210之是否進行第1藥劑與第2藥劑之混合之引起注意功能。標識210、亦即混合促進標識(第1混合促進標識)例如包含「開通確認」等之顯示與上述混合相關之引起注意之文字等。標識210亦可包含「未開封 不可使用」等之字串等。Label 210 is a label that induces the user to mix the first agent and the second agent (i.e., opening of the partition 23). The direction of the text contained in label 210 is inverted when viewed from the front. Therefore, as shown in FIG3, in the multi-chamber container 1 before use, the content of label 210 can be easily identified when viewed from the front. Therefore, for example, when the multi-chamber container 1 is hung on a hook via the hanging hole 4, the attention-drawing function of label 210 as to whether to mix the first agent and the second agent can be fully exerted. Label 210, that is, the mixing promotion label (first mixing promotion label), for example, includes displays such as "opening confirmation" and attention-drawing text related to the above-mentioned mixing. The label 210 may also include a string such as "unopened, do not use".
於本實施形態中，在密封件5之表面，存在顯示方案200之第1區域54、及顯示標識210之第2區域55。第1區域54與第2區域55相互分開，不重疊於缺口52及穿孔線53。於密封件5中第1區域54所占之比例為例如30%以上，於密封件5中第2區域55所占之比例為例如25%以上。該情形下，方案200與標識210各者被合理地顯示。又，於第1區域54中方案200(亦即第1步序201、第2步序202、及第3步序203)所占之比例為例如30%以上。藉此，視認到密封件5(尤其第1區域54)之使用者可容易地著眼於方案200。此外，由於可容易地略讀方案200，故可容易地確認複室容器1之使用方法。另一方面，於第2區域55中標識210所占之比例為60%以上。藉此，視認到密封件5(尤其第2區域55)之使用者不易忽視由標識210實現之引起注意。In this embodiment, on the surface of the seal 5, there is a first area 54 showing the solution 200 and a second area 55 showing the mark 210. The first area 54 and the second area 55 are separated from each other and do not overlap the notch 52 and the perforation line 53. The proportion of the first area 54 in the seal 5 is, for example, more than 30%, and the proportion of the second area 55 in the seal 5 is, for example, more than 25%. In this case, the solution 200 and the mark 210 are each reasonably displayed. In addition, the proportion of the solution 200 (i.e., the first step 201, the second step 202, and the third step 203) in the first area 54 is, for example, more than 30%. Thereby, the user who sees the seal 5 (especially the first area 54) can easily focus on the solution 200. In addition, since the scheme 200 can be easily read, the method of using the multi-chamber container 1 can be easily confirmed. On the other hand, the proportion of the mark 210 in the second area 55 is more than 60%. Thus, the user who sees the sealing member 5 (especially the second area 55) is unlikely to ignore the attention provided by the mark 210.
第1區域54包含：顯示第1步序201及第2步序202之第1部分54a、及連續於第1部分54a且顯示第3步序203之第2部分54b。第1部分54a例如位於較被覆部51更靠近方向Y之密封件5之一端。第1部分54a之形狀無特別限定，例如為大致四角形。第2部分54b例如在方向X上位於較被覆部51靠下側，沿著方向Y延伸。因而，第2部分54b之一部分位於較被覆部51更靠近方向Y之密封件5之另一端。第2部分54b之形狀無特別限定，例如為大致四角形。在第1區域54中第1部分54a所占比例、與在第1區域54中第2部分54b所占比例無特別限制，只要均為30%以上即可。第2區域55例如於方向Y上位於較吊孔4更靠另一側，於方向X上位於較第2部分54b更靠上側。The first area 54 includes: a first portion 54a showing the first step 201 and the second step 202, and a second portion 54b continuing from the first portion 54a and showing the third step 203. The first portion 54a is, for example, located at one end of the sealing member 5 closer to the direction Y than the covering portion 51. The shape of the first portion 54a is not particularly limited, and is, for example, a substantially rectangular shape. The second portion 54b is, for example, located at the lower side of the covering portion 51 in the direction X and extends along the direction Y. Therefore, a portion of the second portion 54b is located at the other end of the sealing member 5 closer to the direction Y than the covering portion 51. The shape of the second portion 54b is not particularly limited, and is, for example, a substantially rectangular shape. The proportion of the first portion 54a in the first area 54 and the proportion of the second portion 54b in the first area 54 are not particularly limited as long as they are both 30% or more. The second area 55 is located, for example, on the other side of the hanging hole 4 in the direction Y and on the upper side of the second portion 54b in the direction X.
於密封件5中，顯示方案200之文字之尺寸、與顯示標識210之文字之尺寸各者為7 pt以上且72 pt以下。該情形下，使用者可容易地確認方案200、與標識210兩者。顯示方案200之文字之尺寸、與顯示標識210之文字之尺寸各者可為10 pt以上，可為18 pt以上，可為24 pt以上，可為36 pt以上，可為64 pt以下，可為56 pt以下，可為48 pt以下，可為40 pt以下。基於使用者可於短時間確認各標識之觀點，第1步序201、第2步序202、第3步序203、及標識210各者中所含之文字數例如為8個文字以下、或6個文字以下。於本實施形態中，顯示方案200之文字之色、與顯示標識210之文字之色互不相同。藉此，色覺異常之使用者不易忽略方案200與標識210兩者。此外，1 pt(點)相當於1/72英吋(約0.35 mm)。又，基於引起使用者注意混合作業之觀點，混合促進標識中所含之文字之尺寸可較方案中所含之文字之尺寸大。In the seal 5, the size of the text displaying the solution 200 and the size of the text displaying the label 210 are each 7 pt or more and 72 pt or less. In this case, the user can easily confirm both the solution 200 and the label 210. The size of the text displaying the solution 200 and the size of the text displaying the label 210 can be 10 pt or more, 18 pt or more, 24 pt or more, 36 pt or more, 64 pt or less, 56 pt or less, 48 pt or less, or 40 pt or less. Based on the viewpoint that the user can confirm each label in a short time, the number of characters contained in each of the first step 201, the second step 202, the third step 203, and the label 210 is, for example, 8 characters or less, or 6 characters or less. In this embodiment, the color of the text of the display scheme 200 and the color of the text of the display logo 210 are different. Thus, users with abnormal color perception are less likely to ignore both the scheme 200 and the logo 210. In addition, 1 pt (point) is equivalent to 1/72 inch (about 0.35 mm). In addition, based on the viewpoint of attracting the user's attention to the mixing operation, the size of the text contained in the mixing promotion logo can be larger than the size of the text contained in the scheme.
端口6係用於排出容器本體2之內容物(例如第1藥劑、或第1藥劑與第2藥劑之混合藥液)之藥劑排出口，設置於複室容器1之下端。端口6係具有例如圓筒形狀之塑膠構件。於端口6，例如設置有可供空心針刺穿且封蓋端口6之注出口之密封塞(未圖示)。此外，於端口6之前端6a貼附密封件7。藉由剝除密封件7，而上述密封塞及抽出口露出。藉由朝該抽出口插入空心針，而容器本體2之第1藥劑與第2藥劑之混合物能夠排出。Port 6 is a medicine discharge port for discharging the contents of the container body 2 (e.g., the first medicine, or a mixed liquid of the first medicine and the second medicine), and is disposed at the lower end of the multi-chamber container 1. Port 6 is a plastic member having, for example, a cylindrical shape. Port 6 is provided with, for example, a sealing plug (not shown) that can be pierced by a hollow needle and seals the injection port of port 6. In addition, a sealing member 7 is attached to the front end 6a of port 6. By removing the sealing member 7, the sealing plug and the extraction port are exposed. By inserting a hollow needle into the extraction port, the mixture of the first medicine and the second medicine in the container body 2 can be discharged.
於以上所說明之本實施形態之複室容器1中，在容器本體2顯示用於將第1藥劑與第2藥劑混合之方案100。藉此，於開始使用複室容器1時等，使用者可容易地確認用於將第1藥劑與第2藥劑混合之具體的方案100。此外，設置於複室容器1之吊孔4由密封件5覆蓋。因此，使用者於使用吊孔4懸吊複室容器1時，自容器本體2去除密封件5之至少一部分(例如，剝離、切取等)。此處，於密封件5亦顯示方案200。因此，於在密封件5之去除作業時使用者視認到密封件5時，可容易地確認用於將第1藥劑與第2藥劑混合之簡潔之方案200。如此，於使用複室容器1時，使用者因可在複數個時序時確認方案100、200，而於藥液之投與前，第1藥劑與第2藥劑之混合作業不易被有意忽略。因此，藉由利用複室容器1，能夠於藥液之投與前良好地防止使用者忘記藥液混合作業。In the multi-chamber container 1 of the present embodiment described above, a scheme 100 for mixing the first agent and the second agent is displayed on the container body 2. Thereby, when starting to use the multi-chamber container 1, etc., the user can easily confirm the specific scheme 100 for mixing the first agent and the second agent. In addition, the hanging hole 4 provided in the multi-chamber container 1 is covered by the sealing member 5. Therefore, when the user hangs the multi-chamber container 1 using the hanging hole 4, the user removes at least a portion of the sealing member 5 from the container body 2 (for example, peels off, cuts off, etc.). Here, a scheme 200 is also displayed on the sealing member 5. Therefore, when the user sees the sealing member 5 during the removal operation of the sealing member 5, the user can easily confirm the simple scheme 200 for mixing the first agent and the second agent. Thus, when using the multi-chamber container 1, the user can confirm the schemes 100 and 200 at multiple times, and the mixing operation of the first and second drugs before the drug solution is administered is not easily overlooked. Therefore, by using the multi-chamber container 1, it is possible to effectively prevent the user from forgetting the drug solution mixing operation before the drug solution is administered.
於本實施形態中，方案100、200各者包含用於將第1藥劑與第2藥劑混合之複數個步序。因而，使用者即便為複雜之混合作業，亦可適切地實施藥液混合作業。In the present embodiment, each of the schemes 100 and 200 includes a plurality of steps for mixing the first agent with the second agent. Therefore, the user can appropriately perform the drug solution mixing operation even if the mixing operation is complicated.
於本實施形態中，密封件5具有覆蓋吊孔4之被覆部51，顯示於密封件5之方案200進一步包含用於將吊孔4露出之第3步序203。因而，當為了利用吊孔4而使用者剝除密封件5時，使用者視認記載於密封件5之方案200之可能進一步變高。因此，於藥液之投與前，第1藥劑與第2藥劑之混合作業更不易被有意忽略。此外，使用者藉由確認第3步序203，可適切地實施吊孔4之露出工序。In this embodiment, the seal 5 has a covering portion 51 covering the hanging hole 4, and the scheme 200 shown on the seal 5 further includes a third step 203 for exposing the hanging hole 4. Therefore, when the user removes the seal 5 in order to use the hanging hole 4, the user is more likely to recognize the scheme 200 recorded on the seal 5. Therefore, before the administration of the drug solution, the mixing operation of the first drug and the second drug is less likely to be intentionally overlooked. In addition, by confirming the third step 203, the user can appropriately implement the process of exposing the hanging hole 4.
於本實施形態中，複室容器1具備摺翼部，該摺翼供設置吊孔4且自容器本體2之一端2a延伸，密封件5將摺翼部3固定於容器本體2上。此外，摺翼部3之寬度較容器本體2之寬度小，密封件5覆蓋摺翼部3。因而，即便於複室容器1之使用前(例如，複室容器1之移送時等)，亦可經由密封件5將摺翼部3確實地固定於容器本體2上。此外，可防止在分隔部23之開通操作之實施前作業者去除封蓋吊孔4之密封件5等之對於複室容器1之非意圖之操作。進而，藉由密封件5固定摺翼部3，可防止由摺翼部3引起之容器本體2之損傷產生。In the present embodiment, the multi-chamber container 1 has a flap portion, the flap portion is provided with a hanging hole 4 and extends from one end 2a of the container body 2, and the sealing member 5 fixes the flap portion 3 to the container body 2. In addition, the width of the flap portion 3 is smaller than the width of the container body 2, and the sealing member 5 covers the flap portion 3. Therefore, even before the multi-chamber container 1 is used (for example, when the multi-chamber container 1 is transferred, etc.), the flap portion 3 can be reliably fixed to the container body 2 via the sealing member 5. In addition, before the opening operation of the partition 23 is performed, the operator can prevent unintentional operations on the multi-chamber container 1, such as removing the sealing member 5 that covers the hanging hole 4. Furthermore, by fixing the flap portion 3 with the sealing member 5, damage to the container body 2 caused by the flap portion 3 can be prevented.
於本實施形態中，在前視下，密封件5之大小為容器本體2之大小之10%以上且20%以下，於密封件5，除方案200外，亦設置促使第1藥劑與第2藥劑之混合之標識210，基於視認性之觀點，於密封件5中，方案200中所含之文字之尺寸、與標識210中所含之文字之尺寸各者可為7 pt以上，亦可為72 pt以下。該情形下，於密封件5，用於將第1藥劑與第2藥劑混合之方案200中所含之文字、與標識210中所含之文字兩者對使用者而言能夠容易地視認。因而，於藥液之投與前，第1藥劑與第2藥劑之混合作業更不易被有意忽略。此外，密封件5之大小為能夠記載所有上述文字。In this embodiment, the size of the seal 5 is 10% or more and 20% or less of the size of the container body 2 in front view. In addition to the scheme 200, the seal 5 is also provided with a label 210 for promoting the mixing of the first and second drugs. From the perspective of visibility, the size of the characters included in the scheme 200 and the size of the characters included in the label 210 in the seal 5 can be 7 pt or more and 72 pt or less. In this case, the characters included in the scheme 200 for mixing the first and second drugs and the characters included in the label 210 in the seal 5 can be easily recognized by the user. Therefore, before the administration of the drug solution, the mixing operation of the first and second drugs is less likely to be intentionally ignored. In addition, the size of the seal 5 is such that all the above texts can be recorded.
於本實施形態中，在容器本體2之表面顯示方案100，在密封件5將摺翼部3固定於容器本體2上時，顯示於容器本體2之方案100中所含之文字之方向、與顯示於密封件5之方案200中所含之文字之方向於上下方向上互為相同。因而，複室容器1之使用者自容器本體2之正側、背側之任一側均可視認方案100、200。In this embodiment, the solution 100 is displayed on the surface of the container body 2. When the sealing member 5 fixes the flap portion 3 to the container body 2, the direction of the text contained in the solution 100 displayed on the container body 2 and the direction of the text contained in the solution 200 displayed on the sealing member 5 are mutually the same in the vertical direction. Therefore, the user of the multi-chamber container 1 can recognize the solutions 100 and 200 from either the front side or the back side of the container body 2.
於本實施形態中，由於容器本體2、第1藥劑及第2藥劑為透明，故於將容器本體2沿著分隔部23摺疊時，能夠視認顯示於容器本體2之方案100與顯示於密封件5之方案200各者。因而，即便於將複室容器1摺疊之情形下，使用者亦可容易地視認方案100、200。In this embodiment, since the container body 2, the first drug, and the second drug are transparent, when the container body 2 is folded along the partition 23, the solution 100 displayed on the container body 2 and the solution 200 displayed on the sealing member 5 can be visually recognized. Therefore, even when the multi-chamber container 1 is folded, the user can easily recognize the solutions 100 and 200.
於本實施形態中，在容器本體2中，在重疊於第1收納部21之第1部分2c與重疊於分隔部23之中央部分2f，顯示方案100中所含之第1步序101，在重疊於第2收納部22之第2部分2d，顯示方案100中所含之第2步序102，分隔部23藉由第1部分2c或第2部分2d經壓迫而可剝離。該情形下，即便於在使用者之壓迫作業中無法視認第1部分2c或第2部分2d之情形下，使用者亦可視認方案100之至少一部分。此外，於重疊於第2收納部22之第3部分2e亦顯示第3步序103。藉此，僅憑藉使用者視認方案100，該使用者便不易忘記經由吊孔4之複室容器1之向掛鉤等之鉤掛。In this embodiment, in the container body 2, the first step 101 included in the scheme 100 is displayed on the first portion 2c overlapping the first storage portion 21 and the central portion 2f overlapping the partition 23, and the second step 102 included in the scheme 100 is displayed on the second portion 2d overlapping the second storage portion 22, and the partition 23 can be peeled off by pressing the first portion 2c or the second portion 2d. In this case, even if the first portion 2c or the second portion 2d cannot be seen during the pressing operation of the user, the user can still see at least a part of the scheme 100. In addition, the third step 103 is also displayed on the third portion 2e overlapping the second storage portion 22. Thus, the user is unlikely to forget to hang the multi-chamber container 1 on the hook through the hanging hole 4, just by visually recognizing the solution 100.
其次，一面參照圖6，一面針對變化例之複室容器進行說明。省略與在變化例之說明中上述之實施形態重複之記載，記載不同之部分。即，於技術上可行之範圍內，可適當使用在變化例中上述之實施形態之記載。Next, the multi-chamber container of the variation is described with reference to FIG6. The descriptions that are repeated with the above-mentioned embodiments in the description of the variation are omitted, and the different parts are described. That is, within the technically feasible range, the descriptions of the above-mentioned embodiments in the variation can be appropriately used.
圖6係變化例之即將使用之前之複室容器之後視圖。圖6所示之複室容器1A就於摺翼部3之背面3a設置標識300之點，與上述實施形態之複室容器1不同。摺翼部3之背面3a係於將摺翼部3向第2收納部22摺疊時與容器本體2相接之面，係在摺翼部3中貼附密封件5之面(表面)的相背側之面。因而，當前視使用前之複室容器1A時，背面3a由密封件5遮擋。另一方面，背面3a於即將使用之前之複室容器1A中露出於外部。設置於背面3a之標識300與上述實施形態之標識210同樣，係促使第1藥劑與第2藥劑之混合之標識(混合促進標識)。於本變化例中，在標識300中，在紅色之背景包含白色空心之文字、記號及圖之至少一者。標識300可為誘導使用者實施第1藥液與第2藥劑之混合(即分隔部23之開通)之標識。標識300介隔著摺翼部3設置於密封件5之相背側。因而，雖未圖示，但前視使用前之複室容器1A時，標識300與背面3a同樣由密封件5遮擋。又，在前視下，在即將使用之前之複室容器1A中，視認設置於摺翼部3之表面之密封件5之一部分，於後視下，在即將使用之前之複室容器1A中，視認設置於摺翼部3之背面3a之標識300。標識300例如直接印刷於背面3a，但不限於此。如圖6所示，於即將使用之前之複室容器1A中，標識300之內容在前視下正立。因此，例如，於經由吊孔4將複室容器1鉤掛於掛鉤等時等，可充分發揮標識300之是否進行第1藥劑與第2藥劑之混合促進功能(引起注意功能)。此外，於本變化例中，標識300之第1部分300a設置於方向Y之摺翼部3之一端部，標識300之第2部分300b設置於方向Y之摺翼部3之另一端部，但不限於此。標識300可具有3個以上之部分，亦可僅具有1個部分。顯示於標識300之混合促進標識(第2混合促進標識)與標識210之混合促進標識同樣。標識300亦可包含「未開封 不可使用」等之字串等。FIG6 is a rear view of a multi-chamber container of a modified example before use. The multi-chamber container 1A shown in FIG6 is different from the multi-chamber container 1 of the above-mentioned embodiment in that a mark 300 is provided on the back surface 3a of the flap portion 3. The back surface 3a of the flap portion 3 is a surface that contacts the container body 2 when the flap portion 3 is folded toward the second storage portion 22, and is a surface opposite to the surface (surface) to which the sealing member 5 is attached in the flap portion 3. Therefore, when the multi-chamber container 1A before use is viewed from the front, the back surface 3a is blocked by the sealing member 5. On the other hand, the back surface 3a is exposed to the outside in the multi-chamber container 1A before use. The label 300 disposed on the back side 3a is the same as the label 210 of the above-mentioned embodiment, and is a label that promotes the mixing of the first drug and the second drug (mixing promotion label). In this variation, the label 300 includes at least one of white hollow text, symbol and figure on a red background. The label 300 can be a label that induces the user to mix the first drug solution and the second drug (i.e., the partition 23 is opened). The label 300 is disposed on the opposite side of the seal 5 via the folding wing portion 3. Therefore, although not shown, when the multi-chamber container 1A is viewed from the front before use, the label 300 is blocked by the seal 5 like the back side 3a. Furthermore, in the front view, in the multi-chamber container 1A before use, a portion of the sealing member 5 provided on the surface of the folding wing portion 3 is visible, and in the rear view, in the multi-chamber container 1A before use, a label 300 provided on the back side 3a of the folding wing portion 3 is visible. The label 300 is, for example, directly printed on the back side 3a, but is not limited thereto. As shown in FIG6 , in the multi-chamber container 1A before use, the content of the label 300 is upright in the front view. Therefore, for example, when the multi-chamber container 1 is hung on a hook via the hanging hole 4, the label 300 can fully exert its function of promoting mixing of the first agent and the second agent (attention-attracting function). In addition, in this variation, the first part 300a of the label 300 is disposed at one end of the flap portion 3 in the direction Y, and the second part 300b of the label 300 is disposed at the other end of the flap portion 3 in the direction Y, but the present invention is not limited thereto. The label 300 may have more than three parts, or may have only one part. The mixing promotion label (second mixing promotion label) displayed on the label 300 is the same as the mixing promotion label of the label 210. The label 300 may also include a string such as "Unopened, Do Not Use".
於以上所說明之變化例中，亦發揮與上述實施形態同樣之作用效果。此外，於即將使用之前之複室容器1A中，標識210位於容器本體2之表面，標識300位於容器本體2之背面。因而，複室容器1A之利用者於摺翼部3之固定解除後，自容器本體2之正側、背側之任一側均可視認上述之混合促進標識(引起注意標識)。換言之，複室容器1A之利用者於摺翼部3之固定解除後，自容器本體2之正側可視認密封件5之標識210，且自容器本體2之背側可視認標識30。因此，於藥液之投與前，第1藥劑與第2藥劑之混合作業更不易被有意忽略。亦即，於變化例中，與上述實施形態進行比較，可謂引起注意功能進一步提高。此外，於上述變化例中，將標識300設置於摺翼部3之背面3a，但不限於此。例如，標識300設置於容器本體2之背面中之在使用前之複室容器1A中由摺翼部3遮蓋之部分。In the variation described above, the same effects as those of the above-mentioned embodiment are also exerted. In addition, in the multi-chamber container 1A just before use, the mark 210 is located on the surface of the container body 2, and the mark 300 is located on the back of the container body 2. Therefore, after the fixation of the flap portion 3 is released, the user of the multi-chamber container 1A can visually recognize the above-mentioned mixing promotion mark (attention-attracting mark) from either the front side or the back side of the container body 2. In other words, after the fixation of the flap portion 3 is released, the user of the multi-chamber container 1A can visually recognize the mark 210 of the sealing member 5 from the front side of the container body 2, and can visually recognize the mark 30 from the back side of the container body 2. Therefore, before the administration of the drug solution, the mixing operation of the first drug and the second drug is less likely to be intentionally ignored. That is, in the variation, compared with the above embodiment, the attention-attracting function is further improved. In addition, in the above variation, the mark 300 is disposed on the back surface 3a of the flap portion 3, but the present invention is not limited thereto. For example, the mark 300 is disposed on the back surface of the container body 2, which is the portion covered by the flap portion 3 in the multi-chamber container 1A before use.
本發明之一態樣之複室容器係例如以下之[1]～[10]所記載般，基於上述實施形態及上述變化例，更詳細地說明其等。 [1]一種複室容器，其係設有吊孔者，且包含： 容器本體，其具有：收納第1藥劑之第1收納部、收納第2藥劑之第2收納部、及將前述第1收納部與前述第2收納部分隔之能夠剝離之分隔部；及 密封件，其覆蓋前述吊孔；且 於前述容器本體與前述密封件各者顯示用於將前述第1藥劑與前述第2藥劑混合之方案。 [2］如[1]之複室容器，其中前述方案包含用於將前述第1藥劑與前述第2藥劑混合之複數個步序。 [3］如[1]或[2]之複室容器，其中前述密封件具有覆蓋前述吊孔之被覆部；且 顯示於前述密封件之前述方案進一步包含用於剝除前述被覆部而將前述吊孔露出之步序。 [4］如[1]至[3]中任一項之複室容器，其進一步包含摺翼部，該摺翼部供設置前述吊孔且自前述容器本體之上緣延伸；且 前述密封件將前述摺翼部固定於前述容器本體上。 [5]如[4]之複室容器，其中前述摺翼部之寬度較前述容器本體之寬度小；且 前述密封件覆蓋前述摺翼部。 [6]如[4]或[5]之複室容器，其中於前述密封件，設置促使前述第1藥劑與前述第2藥劑之混合之第1混合促進標識；且 於在前述摺翼部中貼附前述密封件之面的相背側之背面，設置促使前述第1藥劑與前述第2藥劑之混合之第2混合促進標識。 [7]如[1]至[6]中任一項之複室容器，其中在前視下，前述密封件之大小為前述容器本體之大小之5%以上且30%以下；且 於前述密封件，除前述方案外，亦設置促使前述第1藥劑與前述第2藥劑之混合之混合促進標識； 於前述密封件中，前述方案中所含之文字之尺寸、與前述混合促進標識中所含之文字之尺寸各者為7 pt以上且72 pt以下。 [8]如[4]至[6]中任一項之複室容器，其中於前述容器本體之表面顯示前述方案；且 於前述密封件將前述摺翼部固定於前述容器本體上時，顯示於前述容器本體之前述方案中所含之文字之方向、與顯示於前述密封件之前述方案中所含之文字之方向於上下方向上互為相同。 [9]如[8]之複室容器，其中於將前述容器本體沿著前述分隔部摺疊時，顯示於前述容器本體之前述方案、與顯示於前述密封件之前述方案各者能夠視認。 [10]如[8]或[9]之複室容器，其中於前述容器本體中，在重疊於前述第1收納部之第1部分顯示前述方案之一部分，在重疊於前述第2收納部之第2部分顯示前述方案之另一部分；且 前述分隔部藉由前述第1部分或前述第2部分經壓迫而剝離。A multi-chamber container according to one aspect of the present invention is described in more detail based on the above-mentioned embodiments and the above-mentioned variations, for example, as described in [1] to [10] below. [1] A multi-chamber container having a hanging hole and comprising: A container body having: a first storage portion for storing a first drug, a second storage portion for storing a second drug, and a removable partition portion for separating the first storage portion from the second storage portion; and A sealing member covering the hanging hole; and A scheme for mixing the first drug with the second drug is displayed on each of the container body and the sealing member. [2] A multi-chamber container as in [1], wherein the scheme comprises a plurality of steps for mixing the first drug with the second drug. [3] A multi-chamber container as in [1] or [2], wherein the sealing member has a covering portion covering the hanging hole; and the aforementioned scheme shown in the sealing member further comprises a step for removing the covering portion to expose the hanging hole. [4] A multi-chamber container as in any one of [1] to [3], further comprising a flap portion, the flap portion being provided for the hanging hole and extending from the upper edge of the container body; and the sealing member fixes the flap portion to the container body. [5] A multi-chamber container as in [4], wherein the flap portion has a width smaller than the width of the container body; and the sealing member covers the flap portion. [6] A multi-chamber container as in [4] or [5], wherein a first mixing promotion mark for promoting mixing of the first drug and the second drug is provided on the aforementioned sealing member; and a second mixing promotion mark for promoting mixing of the first drug and the second drug is provided on the back surface opposite to the surface on which the aforementioned sealing member is attached in the aforementioned flap portion. [7] A multi-chamber container as in any one of [1] to [6], wherein the size of the seal is not less than 5% and not more than 30% of the size of the container body when viewed from the front; andIn addition to the above-mentioned solution, a mixing promotion mark is also provided on the seal to promote mixing of the first agent and the second agent;In the seal, the size of the text contained in the above-mentioned solution and the size of the text contained in the mixing promotion mark are each not less than 7 pt and not more than 72 pt.[8] A multi-chamber container as in any one of [4] to [6], wherein the above-mentioned solution is displayed on the surface of the container body; andWhen the seal fixes the flap portion to the container body, the direction of the text contained in the above-mentioned solution displayed on the container body and the direction of the text contained in the above-mentioned solution displayed on the seal are the same in the vertical direction.[9] A multi-chamber container as in [8], wherein when the container body is folded along the partition, the aforementioned solution displayed on the container body and the aforementioned solution displayed on the sealing member are each visibly recognizable.[10] A multi-chamber container as in [8] or [9], wherein in the container body, one part of the aforementioned solution is displayed on the first part overlapping the first storage part, and another part of the aforementioned solution is displayed on the second part overlapping the second storage part; andthe partition is peeled off by the first part or the second part under pressure.
然而，本發明之一態樣不限定於上述實施形態、上述變化例及上述[1]至[10]。本發明之一態樣在不脫離其要旨之範圍內能夠進一步變化。例如，於上述實施形態及上述變化例中，密封件覆蓋吊孔，但不限於此。例如，密封件可僅被用於摺翼部之固定，不覆蓋吊孔。However, one aspect of the present invention is not limited to the above-mentioned embodiments, the above-mentioned variations, and the above-mentioned [1] to [10]. One aspect of the present invention can be further modified within the scope of the gist thereof. For example, in the above-mentioned embodiments and the above-mentioned variations, the sealing member covers the hanging hole, but is not limited thereto. For example, the sealing member can be used only to fix the flap portion without covering the hanging hole.
於上述實施形態及上述變化例中，在密封件設置混合促進標識，但不限於此。例如，可取代密封件，僅於容器本體設置混合促進標識，亦可於密封件與容器本體兩者設置混合促進標識。又，第3步序可僅設置於密封件，亦可僅設置於容器本體。In the above embodiments and variations, the mixing promotion mark is provided on the seal, but the present invention is not limited thereto. For example, the mixing promotion mark may be provided only on the container body instead of the seal, or may be provided on both the seal and the container body. In addition, the third step may be provided only on the seal or only on the container body.
於上述實施形態及上述變化例中，容器本體可進一步具備收容與第1藥劑及第2藥劑不同之藥劑之袋狀之小容器。該小容器例如設置於第1收納部或第2收納部之內部，具有收容上述不同之藥劑之本體、及將該本體之內部與第1收納部或第2收納部分隔之分隔部。該分隔部構成為能夠與容器本體之分隔部之剝離連動剝離。藉此，第1藥劑、第2藥劑及上述不同之藥劑能夠良好地混合。容器本體可具備複數個小容器。該情形下，將一部分之小容器設置於第1收納部之內部，將其他小容器設置於第2收納部之內部。此外，收容於小容器之藥劑例如為含有表面活性劑及脂溶性維他命之藥液、及含有鐵、錳、鋅、銅、碘等微量元素之藥液。In the above-mentioned embodiment and the above-mentioned variation, the container body may further have a bag-shaped small container for accommodating a medicine different from the first medicine and the second medicine. The small container is, for example, arranged inside the first storage part or the second storage part, and has a body for accommodating the above-mentioned different medicines, and a partition part for separating the interior of the body from the first storage part or the second storage part. The partition part is configured to be peeled off in conjunction with the peeling of the partition part of the container body. Thereby, the first medicine, the second medicine and the above-mentioned different medicines can be well mixed. The container body may have a plurality of small containers. In this case, a part of the small containers are arranged inside the first storage part, and the other small containers are arranged inside the second storage part. In addition, the medicine contained in the small container is, for example, a liquid medicine containing a surfactant and a fat-soluble vitamin, and a liquid medicine containing trace elements such as iron, manganese, zinc, copper, and iodine.
1,1A:複室容器 2:容器本體 2a:一端(上緣) 2b:外緣 2c:第1部分(方案100之一部分) 2d:第2部分(方案100之另一部分) 2e:第3部分 2f:中央部分 3:摺翼部 3a:背面 4:吊孔 5:密封件 6:端口 6a:前端 7:密封件 21:第1收納部 22:第2收納部 23:分隔部 23a:中央部 23b:側部 51:被覆部 52:缺口 53:穿孔線 54:第1區域 54a:第1部分 54b:第2部分 55:第2區域 100,200:方案 101,201:第1步序 101a,101b,101c,210,300:標識 102,202:第2步序 103,203:第3步序 300a:第1部分 300b:第2部分 X,Y:方向1,1A: Multi-chamber container2: Container body2a: One end (upper edge)2b: Outer edge2c: Part 1 (one part of solution 100)2d: Part 2 (another part of solution 100)2e: Part 32f: Central part3: Folding wing3a: Back4: Hanging hole5: Seal6: Port6a: Front end7: Seal21: First storage part22: Second storage part23: Partition23a: Central part23b: Side51: Covering part52: Notch53: Perforation line54: First area54a: First part54b: Second part55: Second area100,200: Solution101,201: Step 1101a,101b,101c,210,300: Identification102,202: Step 2103,203: Step 3300a: Part 1300b: Part 2X,Y: Direction
圖1係實施形態之複室容器之前視圖。 圖2係實施形態之複室容器之後視圖。 圖3係即將使用之前之複室容器之前視圖。 圖4係密封件之放大圖。 圖5係顯示經摺疊之複室容器之圖。 圖6係變化例之即將使用之前之複室容器之後視圖。FIG. 1 is a front view of a multi-chamber container of an embodiment.FIG. 2 is a rear view of a multi-chamber container of an embodiment.FIG. 3 is a front view of a multi-chamber container before use.FIG. 4 is an enlarged view of a seal.FIG. 5 is a view showing a folded multi-chamber container.FIG. 6 is a rear view of a multi-chamber container of a variation before use.
1:複室容器1: Multi-chamber container
2:容器本體2: Container body
2a:一端(上緣)2a: one end (upper edge)
2b:外緣2b: External edge
2c:第1部分(方案100之一部分)2c: Part 1 (Part 1 of Scheme 100)
2d:第2部分(方案100之另一部分)2d: Part 2 (another part of Scheme 100)
2e:第3部分2e: Part 3
2f:中央部分2f: Central part
4:吊孔4: Hanging hole
5:密封件5: Seals
6:端口6:Port
6a:前端6a: Front end
7:密封件7: Seals
21:第1收納部21: Storage Section 1
22:第2收納部22: Second storage section
23:分隔部23: Divider
23a:中央部23a: Central part
23b:側部23b: Side
53:穿孔線53: Perforation line
100:方案100: Plan
101:第1步序101: Step 1
101a,101b,101c:標識101a,101b,101c: Identification
102:第2步序102: Step 2
103:第3步序103: Step 3
X,Y:方向X,Y: direction
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023081412AJP2024165311A (en) | 2023-05-17 | 2023-05-17 | Multi-chamber container |
| JP2023-081412 | 2023-05-17 |
| Publication Number | Publication Date |
|---|---|
| TW202448406Atrue TW202448406A (en) | 2024-12-16 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113117562ATW202448406A (en) | 2023-05-17 | 2024-05-13 | Multi-chamber container |
| Country | Link |
|---|---|
| JP (1) | JP2024165311A (en) |
| TW (1) | TW202448406A (en) |
| Publication number | Publication date |
|---|---|
| JP2024165311A (en) | 2024-11-28 |
| Publication | Publication Date | Title |
|---|---|---|
| US7243787B2 (en) | Medicine bag | |
| ES2376691T3 (en) | BLENDER STER CARD PACKAGE FOR CHILDREN AND EASY TO USE FOR OLDER PERSONS. | |
| JP4096200B2 (en) | Medical multi-chamber container and storage bag for storing the same | |
| WO2006118252A1 (en) | Label, medicine bag and storage container with the label | |
| US20090057184A1 (en) | Medicine package | |
| TWI678324B (en) | Sealing label having identification function and container wrapped in the sealing label | |
| US20140081203A1 (en) | Container for administering medication | |
| JP3126232U (en) | Multi-chamber container | |
| WO2005032451A1 (en) | Medical container and its using method | |
| TW202448406A (en) | Multi-chamber container | |
| JP2003321075A (en) | Case for press-through-pack square package | |
| JP2000316951A (en) | Medical bag for chemicals solution | |
| JP2001046468A (en) | Blister pack with cover case | |
| JP2006330715A (en) | Label, medicine bag and storage container with the label | |
| JP4501478B2 (en) | Medical multi-chamber container | |
| JP4649854B2 (en) | Drug bag | |
| JP4379047B2 (en) | Medical container with label attached | |
| JP4822860B2 (en) | Medical multi-chamber container | |
| JP2020503914A (en) | Medical bag with two compartments and tabs | |
| JP2008033115A (en) | label | |
| WO2000044422A1 (en) | Injection tablet item package box and injection tablet stored in item package box | |
| JP2003226360A (en) | Press-through pack package with instruction manual | |
| JP4179218B2 (en) | Medical container | |
| JPH05200095A (en) | Transfusion vessel | |
| JPH10243989A (en) | Chemicals packing body |